AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.59+0.32 (+2.84%)
Close on Oct 19, 2026
- Market cap
- $505.35M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.76 (−24.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Avalo Therapeutics, Inc. saw revenue fall 86.6% to $59.00K over fiscal 2025.
Revenue
$59.00K
-86.6% vs. a year earlier
Operating income
-$91.36M
TTM Q2 2026
EPS, diluted
-$4.75
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $505.35M
- P/E ratio
- –
- Price to sales
- 8565.22
- Price to book
- 1.13
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $59.00K
- Net income
- -$100.33M
- EPS, diluted
- -$4.75
- Book value per share
- $10.29
- Diluted shares
- 44M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$91.36M
Net income
-$100.33M
EPS, diluted
-$4.75
Free cash flow
–
Reported periodTrailing twelve months